Trials / Completed
CompletedNCT00479882
MK-0524B Lipid Study (MK-0524B-063)
A Multicenter, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,414 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed dyslipidemia to demonstrate the effect of MK-0524B compared to MK-0524A + Simvastatin on lipid values.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: simvastatin | |
| DRUG | MK-0524A | Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet |
| DRUG | Placebo | |
| DRUG | MK-0524B |
Timeline
- Start date
- 2007-06-15
- Primary completion
- 2008-06-16
- Completion
- 2008-06-16
- First posted
- 2007-05-28
- Last updated
- 2019-02-06
- Results posted
- 2016-04-01
Source: ClinicalTrials.gov record NCT00479882. Inclusion in this directory is not an endorsement.